Healthcare
Breast Cancer: New Data Reshape Advanced Treatment
EMA backs trastuzumab deruxtecan plus pertuzumab for HER2-positive breast cancer as new trial data reshape treatment options.
EMA backs trastuzumab deruxtecan plus pertuzumab for HER2-positive breast cancer as new trial data reshape treatment options.